Serial Fasciculation Measurements in Motor Neurone Disease

NCT03809845 | Completed

• 1 other identifier: KCH17-105
• Study Type: interventional
• Target: 25
• Locations: 1 country
• Sites: 1

Brief Summary

Patients with motor neurone disease (MND) typically experience relentless motor decline and die within three years of symptom onset from respiratory muscle weakness. There are currently no effective therapies and the discovery of novel therapies is hampered by the lack of a sensitive disease biomarker. Consequently, there is a huge drive to discover novel biomarkers, which can reliably track disease progression over time. These can then be incorporated into clinical drug trials to expedite effective drug discovery. Muscle fasciculations represent the hyperexcitability of diseased motor neurons and are almost universally present from the early stages of MND. The investigators predict that the site, frequency and shape of fasciculations might provide a sensitive measure of disease progression in an individual. In order to calibrate this technique, the investigators will conduct a 12-month longitudinal study, recruiting 24 patients from the King's College Hospital Motor Nerve Clinic, comprising a mixture of patients with MND and those with benign fasciculation syndrome. Patients in this latter group have fasciculations but do not develop weakness and have normal lifespans. They are therefore an optimal control group. At each visit, the investigators will take resting HDSEMG recordings from all four limbs and perform standard clinical measures of disease progression. The investigators will also monitor the decline in motor unit number using a newly validated neurophysiological technique, called Motor Unit Number Index (MUNIX).

Conditions

Motor Neuron Disease; Benign Fasciculation-Cramp Syndrome

Outcome Measures

Primary Outcomes (1)

• Change in fasciculation frequency over time

  To characterise the frequency of fasciculations in patients with motor neurone disease and to determine whether these parameters correlate with the trajectory of disease progression over a 12-month period.

  12 months

Secondary Outcomes (5)

• Change in fasciculation morphology over time

  12 months

• Change in Functional Rating Scale (FRS) over time

  12 months

• Change in motor unit number index measurements over time

  12 months

• Change in MRC power sum score over time

  12 months

• Change in slow vital capacity over time

  12 months

Study Arms (2)

Motor neuron disease

ACTIVE COMPARATOR

Device: High-density surface electromyography

Benign fasciculation syndrome

ACTIVE COMPARATOR

Device: High-density surface electromyography

Interventions

High-density surface electromyography DEVICE

High-density surface electromyography

Benign fasciculation syndrome; Motor neuron disease

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• (i) Aged between 40 and 80 years of age inclusive, at the time of signing the informed consent.
• (ii) Diagnosed with MND by a neurologist with expertise in MND.(20) For subjects with bulbar onset there must be objective limb involvement of at least one limb.
• (iii) Diagnosed with MND within 24 months of symptom onset. (iv) Subjects must be ambulatory (i.e. must not be confined to a wheelchair). (v) Male and female subjects (vi) Capable of giving signed informed consent (vii) Capable and willing to comply with the requirements of the protocol (either by themselves or with assistance).
• (i) Aged between 18 and 80 years of age inclusive, at the time of signing the informed consent.
• (ii) Diagnosed with BFS by a neurologist with expertise in motor nerve disorders.
• (iii) Male and female subjects (vi) Capable of giving signed informed consent (vii) Capable and willing to comply with the requirements of the protocol (either by themselves or with assistance).

You may not qualify if:

• (i) Neurological (other than the subject's MND) or non-neurological co-morbidities (e.g. joint disease, respiratory disease) which limit mobility.
• (ii) Clinically significant cognitive impairment in the opinion of the investigator or lacking capacity in accordance with the Mental Capacity Act (2005).
• (iii) Regionally restricted forms of MND, or other atypical variants:
• Isolated corticobulbar pattern of MND with normal ambulation
• Primary lateral sclerosis
• Signs of chronic partial denervation restricted to a single limb
• MND or parkinsonism dementia complex (iv) Subjects requiring mechanical ventilation (non-invasive ventilation for sleep apnoea is allowed).
• (v) Historical or current evidence of clinically significant uncontrolled disease which, in the opinion of the chief investigator, would put the safety of the subject at risk through participation or impact the study assessments or endpoints.
• (vi) Presence of an active implantable cardiac medical device (e.g., pacemaker or implantable cardioverter-defibrillator) or at a high risk for needing external defibrillation.
• (vii) History of skin hypersensitivity to adhesives. (viii) Current participation in a clinical trial which in the opinion of the chief investigator might impact the objectives of this study.
• (i) Significant diagnostic uncertainty, whereby motor neurone disease remains a possible differential diagnosis.
• (ii) Historical or current evidence of clinically significant uncontrolled disease which, in the opinion of the chief investigator, would put the safety of the subject at risk through participation or impact the study assessments or endpoints.
• (iii) Presence of an active implantable cardiac medical device (e.g., pacemaker or implantable cardioverter-defibrillator) or at a high risk for needing external defibrillation.
• (iv) History of skin hypersensitivity to adhesives. (v) Current participation in a clinical trial which in the opinion of the chief investigator might impact the objectives of this study.

Sponsors & Collaborators

• King's College Hospital NHS Trust: lead

Study Sites (1)

King's College Hospital NHS Foundation Trust

London, United Kingdom

Location

MeSH Terms

Conditions

Motor Neuron Disease; Neuromuscular Diseases

Condition Hierarchy (Ancestors)

Neurodegenerative Diseases; Nervous System Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: 20 Motor Neuron Disease (MND) patients and 5 Benign Fasciculation Syndrome (BFS) patients undergoing same assessments at 2-monthly intervals for one year

Study Record Dates

• First Submitted: March 13, 2018
• First Posted: January 18, 2019
• Study Start: July 6, 2017
• Primary Completion: March 1, 2019
• Study Completion: March 1, 2019
• Last Updated: August 21, 2019

Record last verified: 2019-08

Locations

GB (1)